Navigation Links
Pharma Manufacturing Quality: Optimizing Processes for FDA Compliance
Date:4/18/2008

CHAPEL HILL, N.C., April 18 /PRNewswire/ -- With safety issues making headlines, pharmaceutical and medical device manufacturers face a rugged regulatory landscape. Organizations are relying on their quality function to navigate regulatory difficulties that could affect production. Proper staffing of quality roles is just one way organizations optimize their quality function and a study by pharmaceutical benchmarking leader Best Practices, LLC found best-in-class companies have a ratio of quality personnel to total manufacturing employees between 1:4 and 1:7.

As captured in the benchmarking report, The Quality Function: Structure, Staffing and Execution, Best Practices, LLC, reveals strategic best practices in quality harnessed from survey responses and in-depth interviews with seven top pharmaceutical and medical device company leaders. A complementary excerpt is available at http://www3.best-in-class.com/rr930.htm .

Executives from Abbott, Lilly, J&J, GlaxoSmithKline, Wyeth and others shared wisdom and key insights for honing elite quality functions within their organizations. A sampling of their tactics and best practices includes:
* Heighten intra- and inter-company transparency: Disseminate

information about weak areas within the company and competitor

companies among quality staff, as reflected in regulatory consent

decrees and warning letters obtained from FDC publications and

Gold/Green/Pink Sheets.

* Establish action-triggering metrics: Develop reporting mechanisms that

bring performance measurements and deviation reports before the eyes of

senior management.

* Focus quality personnel on activities/results not measures: Employ

integrated improvement charts to effectively communicate important

measures to focus actions by responsible parties. E.g., 3-in-1 charts

T
'/>"/>

SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)...t. 6 /PRNewswire/ -- Developed in collaboration wi...ades, CA is introducing,Revolutionary Breast Surfa...c Surgery office of Dr. Steve Laverson this week i...he first of its kind, and is based on,breakthrough...with,innovative proprietary software. The XS-300(T...
(Date:10/6/2008)...ct. 6 /PRNewswire/ -- The organizers of Informex a...e on Global Sourcing for the,Pharmaceutical Indust...inceton Marriott in New Jersey USA., The conferen... the,Global Sourcing Council, and boasts an unpara...e likes of Johnson & Johnson, Bristol Myers Squibb...
(Date:10/6/2008)... LegalView recently posted detailed inform...he potentially serious side effects caused by the ... the drug,s potential side effects are the develop... for young adult and child patients. , ...- LegalView, the number one resource for everythin...
(Date:10/6/2008)... Hospital Ship Serving in West Africa Rece...Garden Valley, Texas October 6, 2008 -- www.seamob...l provider of communications services to remote lo...s to the FoxNews channel via satellite to Mercy Sh...ica Mercy. The Africa Mercy is the world,s larges...
Breaking Medicine News(10 mins):Health News:Plan Your Breasts in 3-D 2Health News:Global Sourcing Strategies for the Pharmaceutical Industry 10th - 11th November, Marriott Princeton, New Jersey USA 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 3Health News:Seamobile Provides Foxnews To Mercy Ships 2Health News:Seamobile Provides Foxnews To Mercy Ships 3
... University of Liverpool had proposed that patient...t from medication.// They say that it is advisable...ptic patients. Researchers of the study feel that ...ficantly benefit the patients in having a better q...
...ccess of the World Health Day 2000 with the theme ...orld Blood Donors Day.// The date coincides with t...the ABO blood group system. The International Bl...y by the International Federation of Blood Donor O...
... analysis has been developed as a tool to diagnose...and Harvard. Researchers have also been able to de...icroRNA profile through an easy and not expensive ... small RNA molecules that control the level of pro...
...n reduce the rate of negative appendectomy by a si... imaging is also known as Computerized Axial Tomog...sectional images that may be used as a diagnostic ...iseases and health conditions. Negative appendecto...
Other Medicine News:
(Date:10/2/2008)...XFORD, England, October 2 /- Circassi...ed on the fields of allergy and critical,care, tod...cal study of its,ToleroMune(R) technology in the f...results achieved in an earlier phase II study, whi... the ToleroMune approach to allergy,desensitizatio...
(Date:10/1/2008)...AMBRIDGE, Mass., Oct. 1 /- Ironwood P... $50 million in a private equity financing.,This c...se 3 development,program evaluating linaclotide fo...onstipation (IBS-C) and chronic constipation (CC),...covered drug candidates, and to,expand commercial ...
(Date:10/1/2008)...ALIFAX, Oct. 1 / ImmunoVaccine Techno...DepoVax(TM) is showing positive,pre-clinical resul...tic,cancer and several infectious disease vaccine ...nted October 4th at the Ehrlich II conference in,G... will also be reporting,on the capabilities of IVT...
(Date:10/1/2008)...nces in diagnostics and genetic testing give women... risks, DAYTON, Ohio, Oct. 1 /- Ac...p (2007), an estimated 182,460 new cases of breast...8. And while screening,programs are resulting in t...e easily and successfully treated, breast cancer c...
Breaking Medicine Technology:Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology 2Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3 2Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3 3ImmunoVaccine Technologies' DepoVax(TM) Shows Positive Results for Cancer and Infectious Diseases 2Good Samaritan Hospital Launches High Risk Breast Cancer Program at Good Samaritan North Health Center 2Good Samaritan Hospital Launches High Risk Breast Cancer Program at Good Samaritan North Health Center 3Good Samaritan Hospital Launches High Risk Breast Cancer Program at Good Samaritan North Health Center 4Study reveals surprising details of the evolution of protein translation 4435 1Study reveals surprising details of the evolution of protein translation 4435 2AdvaMed 2008 Supporting Partner Organizations Up 30 25 Over Last Year 25347 1AdvaMed 2008 Supporting Partner Organizations Up 30 25 Over Last Year 25347 2AdvaMed 2008 Supporting Partner Organizations Up 30 25 Over Last Year 25347 3AdvaMed 2008 Supporting Partner Organizations Up 30 25 Over Last Year 25347 4Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus 2825 1Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus 2825 2Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus 2825 3Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus 2825 4Temple Fox Chase and Geisinger create Keystone Institute for Translational Medicine 25344 1Temple Fox Chase and Geisinger create Keystone Institute for Translational Medicine 25344 2
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons.
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons.
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons.
Each handle is designed to fit a specific trephine size.
Medicine Products: